Moleculin Biotech, Inc.
A late-stage pharmaceutical company developing drugs for resistant cancers and viruses.
MBRX | US
Overview
Corporate Details
- ISIN(s):
- US60855D2009
- LEI:
- Country:
- United States of America
- Address:
- 5300 MEMORIAL DRIVE, 77007 HOUSTON
- Website:
- https://moleculin.com/
- Sector:
- Manufacturing
Description
Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Moleculin Biotech, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Moleculin Biotech, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Moleculin Biotech, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
